Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (41-50 of 198) with videos related to

Pageof 20
Sort By:
BMC Bioinformatics|March 1, 2017
3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire dataLi Zhang, Jason Cham, Alan Paciorek, et al.
Age and Ageing|January 3, 2026
Supporting safe walking and managing missing incidents in dementia: a qualitative narrative synthesis of current evidenceHoi Tat Kwok, Annika Dhawan, Valerie Lye, et al.
Journal of Virology|October 9, 2002
Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligationLawrence Fong, Manuela Mengozzi, Nancy W Abbey, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 29, 2020
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?Daniel Vargas P de Almeida, Lawrence Fong, Matthew B Rettig, et al.
Science Translational Medicine|May 30, 2014
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsEdward Cha, Mark Klinger, Yafei Hou, et al.
Age and Ageing|May 12, 2026
Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UKVasiliki Orgeta, Garrett Kidd, Jean Stafford, et al.
Journal for Immunotherapy of Cancer|February 9, 2022
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapyRyan C Augustin, Robert D Leone, Aung Naing, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Molecular Pharmaceutics|February 5, 2021
Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor ImmunityElizabeth S Levy, Ryan Chang, Colin R Zamecnik, et al.
Clinical Genitourinary Cancer|January 7, 2024
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate CancerChitra Priya Emperumal, Alessandro Villa, Caleb Hwang, et al.
Pageof 20

Showing results (41-50 of 198) with videos related to

Sort By:
Pageof 20
BMC Bioinformatics|March 1, 2017
3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire dataLi Zhang, Jason Cham, Alan Paciorek, et al.
Age and Ageing|January 3, 2026
Supporting safe walking and managing missing incidents in dementia: a qualitative narrative synthesis of current evidenceHoi Tat Kwok, Annika Dhawan, Valerie Lye, et al.
Journal of Virology|October 9, 2002
Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligationLawrence Fong, Manuela Mengozzi, Nancy W Abbey, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 29, 2020
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?Daniel Vargas P de Almeida, Lawrence Fong, Matthew B Rettig, et al.
Science Translational Medicine|May 30, 2014
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patientsEdward Cha, Mark Klinger, Yafei Hou, et al.
Age and Ageing|May 12, 2026
Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UKVasiliki Orgeta, Garrett Kidd, Jean Stafford, et al.
Journal for Immunotherapy of Cancer|February 9, 2022
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapyRyan C Augustin, Robert D Leone, Aung Naing, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Molecular Pharmaceutics|February 5, 2021
Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor ImmunityElizabeth S Levy, Ryan Chang, Colin R Zamecnik, et al.
Clinical Genitourinary Cancer|January 7, 2024
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate CancerChitra Priya Emperumal, Alessandro Villa, Caleb Hwang, et al.
Pageof 20